Associate Professor Jonathan Emberson
BA, MSc, PhD
Associate Professor, Medical Statistics and Epidemiology
- MRC PHRU Programme Leader
- NDPH Deputy Director of Graduate Studies
- Clinical Trial Service Unit
- MSc in Global Health Science Module Lead: Clinical Trials and Meta-Analysis
Jonathan is an Associate Professor of Medical Statistics and Epidemiology within the Nuffield Department of Population Health. After graduating in Mathematics in 1998, he studied statistics and epidemiology at MSc and PhD level before joining the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) in 2004.
His main research involves studying the causes and prevention of cardiovascular diseases through the design, conduct and analysis of large-scale observational cohort studies, randomised controlled trials, and individual-participant-data meta-analyses of both types of study. In particular, he is the UK Principal Investigator and MRC Population Health Research Unit (MRC-PHRU) Programme Leader for the Mexico City Prospective Study, a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.
Al-Shahi Salman R. et al, (2019), Lancet Neurol, 18, 643 - 652
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial.
RESTART Collaboration None., (2019), Lancet (London, England), 393, 2613 - 2623
Body Fat Distribution and Systolic Blood Pressure in 10,000 Adults with Whole-Body Imaging: UK Biobank and Oxford BioBank.
Malden D. et al, (2019), Obesity (Silver Spring)
Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial.
Kitas GD. et al, (2019), Arthritis Rheumatol
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int